Heron Therapeutics Inc. (NASDAQ:HRTX)’s share price was up 4.7% during mid-day trading on Wednesday . The company traded as high as $17.66 and last traded at $17.39, with a volume of 159,212 shares changing hands. The stock had previously closed at $16.61.

A number of equities analysts have issued reports on HRTX shares. Brean Capital reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Monday, April 18th. Leerink Swann reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Tuesday, April 19th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Sunday, May 8th. Cowen and Company reaffirmed a “buy” rating and issued a $47.00 price objective on shares of Heron Therapeutics in a research note on Sunday, April 17th. Finally, Noble Financial reaffirmed a “buy” rating and issued a $51.00 price objective on shares of Heron Therapeutics in a research note on Wednesday, April 20th. One analyst has rated the stock with a sell rating, nine have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $50.30.

The company’s 50 day moving average is $17.63 and its 200-day moving average is $19.07.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Thursday, May 5th. The biotechnology company reported ($0.92) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.92). Analysts anticipate that Heron Therapeutics Inc. will post ($3.59) earnings per share for the current fiscal year.

A number of institutional investors have made changes to their positions in the stock. Swiss National Bank acquired a new position in shares of Heron Therapeutics during the fourth quarter valued at about $1,100,000. GAM Holding AG boosted its position in shares of Heron Therapeutics by 28.9% in the fourth quarter. GAM Holding AG now owns 41,900 shares of the biotechnology company’s stock valued at $1,119,000 after buying an additional 9,400 shares during the period. Russell Frank Co boosted its position in shares of Heron Therapeutics by 46.9% in the fourth quarter. Russell Frank Co now owns 48,830 shares of the biotechnology company’s stock valued at $1,369,000 after buying an additional 15,585 shares during the period. California State Teachers Retirement System boosted its position in shares of Heron Therapeutics by 1.9% in the fourth quarter. California State Teachers Retirement System now owns 54,211 shares of the biotechnology company’s stock valued at $1,447,000 after buying an additional 1,000 shares during the period. Finally, California Public Employees Retirement System boosted its position in shares of Heron Therapeutics by 863.8% in the fourth quarter. California Public Employees Retirement System now owns 90,600 shares of the biotechnology company’s stock valued at $2,419,000 after buying an additional 81,200 shares during the period.

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.